Anders/Marzan: Thanks for the reply!
With unblinded TLD, isn’t a one drug company in possession of about as material non-public information as you can get?
Wouldn’t this mean they would have to be very careful with what they do with this information or with any other action material to the company.
Isn’t the reason why most companies don’t sit on good TLD forever because it ties the company’s hands as to what they can do going forward?
Isn’t that why they said “as soon as possible” in the 10/5 PR?
Wouldn’t actions that could be legally suspect include negotiation of changes in warrant structure/amounts, anything that would affect total float, any offering or financing arrangement for that matter, or really anything that would require disclosure of TLD to anyone before disclosure to everyone?
I do realize that they could do NDAs with the other parties, but there is still risks of trying to use a contract to limit disclosure of material information before it is disclosed to the shareholders/public?
OR
Is it pretty much a free for all as long as TLD isn’t failed they can delay for as long as they want?
Market Data 
Markets 
AI
